The European Medicines Agency strongly recommends administration of @entity4350 through a central venous catheter (CVC) to minimize the risk of extravasation. However, CVCs place @entity1 at risk of catheter-related complications and have a significant budgetary impact for oncology departments. The most frequently used CVCs are subcutaneously implanted PORT-chamber catheters (PORTs); peripherally inserted central venous catheters (PICCs) are relatively new. We reviewed data of @entity4350 -treated @entity1 to evaluate the relative cost-effectiveness of the use of PORTs and PICCs in six Italian centres. Data on 102 @entity4350 -treated @entity1 (20 with @entity242 , 80 with @entity43 and two with @entity5 ) were evaluated. Forty-five @entity1 received @entity4350 by a PICC, inserted by trained nurses using an ultrasound-guided technique at the bedside, whereas 57 @entity1 received @entity4350 infusion by a PORT, requiring a day surgery procedure in the hospital by a surgeon. @entity1652 and @entity281 were reported in four @entity1 , equally distributed between PORT or PICC users. @entity715 occurred in a single @entity1 with a PORT. Complications requiring devices removal were not reported during any of the 509 cycles of therapy (median 5; range 1-20). PICC misplacement or early malfunctions were not reported during @entity4350 infusion. The cost-efficiency ratio favours PORT over PICC only when the device is used for more than 1 year. Our data suggest that @entity4350 infusion by PICC is safe and well accepted, with a preferable cost-efficiency ratio compared with PORT in @entity1 requiring short-term use of the device ( <=1 year).

A retrospective analysis of XXXX infusion by peripherally inserted central venous catheters: a multicentric Italian experience.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity4350 :: ('MESH:C099150', 'Chemical') :: ['trabectedin'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cervical cancer'] @entity1652 :: ('MESH:D009471', 'Disease') :: ['Device dislocation'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infections'] @entity715 :: ('MESH:D013927', 'Disease') :: ['Thrombosis']
@entity4350 :: (MESH:C099150,Chemical) :: ['trabectedin']
